Title: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic
treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis
Version: 5 Date: 03 Feb 2022
Reviewer's report:
Authors had answered all the question and I had no further comments.
Title: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic
treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis
Version: 5 Date: 03 Feb 2022
Reviewer's report:
Authors had answered all the question and I had no further comments.
Please review this paper.
user
Title: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic
treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis
Version: 5 Date: 03 Feb 2022
Reviewer's report:
Authors had answered all the question and I had no further comments.
assistant